Klotho: strong longevity genetics, no human anti-ageing therapy yet

Klotho is one of the better-supported longevity genes in the laboratory, and it has a genuine human signal — but that signal is a variant of a gene people are born with, not a drug anyone has shown to work in people [s1][s2]. The strongest step toward therapy so far is a single dose of klotho protein that improved memory in aged monkeys; there is no completed human trial [s3]. Held together, that makes klotho a promising target and an unproven treatment, which is exactly the gap the supplement market papers over.

A gene that behaves like an ageing switch in mice

The gene got its name — after Clotho, the Greek fate who spins the thread of life — from what happens when it fails. Mice engineered to lose klotho function develop a syndrome that resembles premature human ageing, with arteriosclerosis, thin bones, wasting and a short life [s4]. That 1997 finding established klotho as a gene whose absence accelerates ageing, and it is why raising klotho became an obvious thing to try [s4].

The cognition work is more striking still. Mice engineered to overexpress klotho throughout the body outperformed normal mice on tests of learning and memory, showed stronger long-term potentiation — a cellular signature of memory formation — and had more of a specific NMDA-receptor subunit, GluN2B, at their synapses [s2]. When that subunit was blocked, the benefit disappeared, pinning the effect to a defined mechanism rather than a vague vigour [s2]. Notably, the boost showed up in young mice too, suggesting klotho enhances cognition somewhat independently of the ageing process it also slows [s2].

The human evidence is genetic, and cuts both ways

In humans the finding is a common functional variant called KL-VS [s1]. A 2002 study across three populations reported that people carrying two copies of it were underrepresented among the elderly — a hint that the double dose is disadvantageous for reaching old age [s1]. Yet carrying a single copy points the other way: heterozygous carriers of KL-VS have higher circulating klotho and, in the 2014 work, measurably better cognition than non-carriers [s2]. So the human data describe a variant with a dose-dependent, double-edged effect — not a smooth "more klotho is better" story, and certainly not a demonstration that adding klotho to an adult helps [s1][s2].

A genetic association of this kind tells you about a lifetime spent with a variant, from conception onward, and about the level of klotho that variant sets in the blood [s1][s2]. That is a robust thing to know, but a limited one. It cannot tell you what happens when you give the protein to a 70-year-old who has spent decades without it — which is the only question a therapy actually has to answer, and the one no human study has yet addressed [s3].

The monkey result — and its limits

The closest anyone has come is a 2023 study in aged rhesus monkeys [s3]. The researchers first confirmed the monkey form of the protein worked in mice, then gave old monkeys a single injection [s3]. A low dose improved memory; a high dose did not [s3]. That the low dose worked and the higher one failed is a real result, but a non-monotonic dose-response from a single acute injection in a small primate study is a reason for caution, not celebration — it is the opposite of the clean "more equals better" curve a drug developer wants to see [s3].

There are hard obstacles between here and a pill or shot. Klotho is a large protein that does not readily cross from the blood into the brain, the human evidence is association rather than intervention, and no randomised human trial has yet reported [s1][s2][s3]. Anything sold today as a "klotho booster" is trading on the laboratory headline while skipping the step — a human trial — that would show it does anything at all.

Klotho is best read as one entry in the broader hallmarks-of-ageing framework, a real mechanism with a real human genetic footprint, alongside the gene variants found in centenarians. Its trajectory so far mirrors that of young blood and plasma exchange — a compelling animal signal that thins out on contact with human evidence — and it is a useful test of any biological-age or longevity test that claims to read klotho as a dial you can turn.